The AHFIRM Study: Investigational Drug to Treat Alcoholic Hepatitis

Clinical Trial Title

A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis

National Clinical Trial Number:


Contact Information

Diana Goldman, RN

Clinical Trial Protocol Description:

This is a study to evaluate the safety and efficacy of the investigational drug, DUR-928, in subjects with severe alcohol-associated hepatitis. This is a study that takes place in the hospital.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have been admitted in the hospital with alcoholic hepatitis.
  • Have a serum total bilirubin > 3.0 mg/dL.
  • Have a Model for End-stage Liver Disease (MELD) score between 21-30.

You will be excluded from the study if any of the following criteria apply to you:

  • Have taken corticosteroids for a duration exceeding 7 days in the past 30 days.
  • Are experiencing alcohol withdrawal symptoms or on treatment according to CIWA protocol.
  • Have an active infection.
  • Have a serum creatinine >2.5 mg/dL or be on hemodialysis (CVVH).

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Costica Aloman, MD

Contact Information

Diana Goldman, RN


Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more